fda compounding restrictions bpc 157 BPC-157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank BREAKING: The FDA just reversed

BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA Compliance for Peptide Therapy and BPC 157 Holt Law A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them

SKU: 55542809124 · From centoria.fr